

=> d his

(FILE 'HOME' ENTERED AT 10:11:44 ON 21 JUL 2005)

FILE 'HCAPLUS' ENTERED AT 10:12:00 ON 21 JUL 2005
 L1 1 (US2004096519 OR US6680073)/PN OR US99-128604#/AP, PRN
 E TARBET B/AU
 L2 59 E4-6
 L3 1 L2 AND ONYCHO?
 L4 1 L1 OR L3

FILE 'REGISTRY' ENTERED AT 10:14:30 ON 21 JUL 2005

FILE 'HCAPLUS' ENTERED AT 10:14:32 ON 21 JUL 2005
 L5 TRA L4 1- RN : 10 TERMS

FILE 'REGISTRY' ENTERED AT 10:14:32 ON 21 JUL 2005
 L6 10 SEA L5

FILE 'WPIX' ENTERED AT 10:14:35 ON 21 JUL 2005
 L7 2 (US2004096519 OR US6680073)/PN OR US99-128604#/AP, PRN
 E TARBET B/AU
 L8 29 E3-5
 L9 2 L8 AND ONYCH?
 L10 2 L7 OR L9

=> b hcap

FILE 'HCAPLUS' ENTERED AT 10:15:50 ON 21 JUL 2005
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 21 Jul 2005 VOL 143 ISS 4
 FILE LAST UPDATED: 20 Jul 2005 (20050720/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all 14

L4 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 2004:54242 HCAPLUS
 DN 140:99596
 ED Entered STN: 22 Jan 2004
 TI Composition and method for the treatment of onychomycosis in animals
 IN Tarbet, Bryon J.
 PA USA
 SO U.S., 4 pp.
 CODEN: USXXAM
 DT Patent
 LA English
 IC ICM A01N059-20

INCL 424630000; 424405000; 424406000; 424613000; 424616000; 424631000;
424638000; 424642000; 424641000; 424646000

CC 63-5 (Pharmaceuticals)

Section cross-reference(s): 1, 5

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6680073	B1	20040120	US 2000-545486	20000410 <--
	US 2004096519	A1	20040520	US 2003-706708	20031111 <--
PRAI	US 1999-128604P	P	19990408 <--		
	US 2000-545486	A3	20000410		

CLASS

	PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
	US 6680073	ICM	A01N059-20
		INCL	424630000; 424405000; 424406000; 424613000; 424616000; 424631000; 424638000; 424642000; 424641000; 424646000
	US 6680073	NCL	424/630.000; 424/405.000; 424/406.000; 424/613.000; 424/616.000; 424/631.000; 424/638.000; 424/641.000; 424/642.000; 424/646.000; 424/648.000; 514/159.000; 514/165.000; 514/731.000
		ECLA	A61K031/30; A61K033/40 <--
	US 2004096519	NCL	424/638.000; 424/616.000; 514/355.000; 514/423.000
		ECLA	A61K031/30; A61K033/40 <--

OS MARPAT 140:99596

AB This invention relates to a composition and method for the treatment of white line disease, including ailments such as Onychomycosis, sporotrichosis, hoof rot, jungle rot, pseudallescheria boydii, scopulariopsis or athletes foot. The composition of the present invention is useful for the treatment of fungal infections such as Onychomycosis in warm blooded animals such as humans and horses. The method of the present invention is directed to the application of a therapeutic amount of the present composition. In one of the examples provided, the treatment solution is prepared from salicylic acid, NaOH, boric acid and hydrogen peroxide.

ST nail hoof fungus infection treatment soln salicylate peroxide

IT Hoof

(fungal infection; solns. for treatment of onychomycosis in animals)

IT Mycosis

Nail (anatomical), disease
(onychomycosis; solns. for treatment of onychomycosis in animals)

IT Equus caballus

Human

Mycosis

(solns. for treatment of onychomycosis in animals)

IT Borates

Peroxides, biological studies

Transition metal complexes

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(solns. for treatment of onychomycosis in animals)

IT 69-72-7, Salicylic acid, biological studies 69-72-7D, Salicylic acid, derivs. 636-32-8, 1,2,4,5-Tetrahydroxybenzene 7439-89-6D, Iron, complexes 7440-48-4D, Cobalt, complexes 7440-50-8D, Copper, complexes 7440-66-6D, Zinc, complexes 7722-84-1, Hydrogen peroxide., biological studies 7758-98-7, Copper sulfate, biological studies 10043-35-3, Boric acid, biological studies 26062-79-3, Polydadmac
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(solns. for treatment of onychomycosis in animals)

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Benignus; US 2457025 A 1948 HCPLUS
- (2) Bernstein; US 2809971 A 1957 HCPLUS
- (3) Gans; US 5648389 A 1997 HCPLUS
- (4) Grier; US 3297525 A 1967 HCPLUS

7 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> b wpix

FILE 'WPIX' ENTERED AT 10:16:16 ON 21 JUL 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE LAST UPDATED: 20 JUL 2005 <20050720/UP>
MOST RECENT DERWENT UPDATE: 200546 <200546/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,
PLEASE VISIT:
[<<<](http://www.stn-international.de/training_center/patents/stn_guide.pdf)

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE
[<<<](http://thomsonderwent.com/coverage/latestupdates/)

>>> FOR INFORMATION ON ALL DERWENT WORLD PATENTS INDEX USER
GUIDES, PLEASE VISIT:
[<<<](http://thomsonderwent.com/support/userguides/)

>>> NEW! FAST-ALERTING ACCESS TO NEWLY-PUBLISHED PATENT
DOCUMENTATION NOW AVAILABLE IN DERWENT WORLD PATENTS INDEX
FIRST VIEW - FILE WPIFV.
FOR FURTHER DETAILS: [<<<](http://www.thomsonderwent.com/dwpifv)

>>> THE CPI AND EPI MANUAL CODES HAVE BEEN REVISED FROM UPDATE 200501.
PLEASE CHECK:
[FOR DETAILS. <<<](http://thomsonderwent.com/support/dwpiref/reftools/classification/code-revision/)

'BIX BI,ABEX' IS DEFAULT SEARCH FIELD FOR 'WPIX' FILE

=> d all l10 tot

L10 ANSWER 1 OF 2 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN
AN 2004-439503 [41] WPIX
CR 2004-106341 [11]
DNC C2004-164549
TI Composition, useful to treat e.g. **onychomycosis**, comprises
aryloxy derivative, copper composition, peroxide, polyhydroxy aromatic
compound, transition metal coordination composition and hydrophylllic
carrier.
DC A96 B05 C03
IN TARRET, B J
PA (TARB-I) TARRET B J
CYC 1
PI US 2004096519 A1 20040520 (200441)* 5 A61K033-40 <-
ADT US 2004096519 A1 Provisional US 1999-128604P 19990408, Div ex US
2000-545486 20000410, US 2003-706708 20031111
FDT US 2004096519 A1 Div ex US 6680073
PRAI US 1999-128604P 19990408; US 2000-545486
20000410; US 2003-706708 20031111
IC ICM A61K033-40
ICS A61K033-34
AB US2004096519 A UPAB: 20040629
NOVELTY - Composition (C) for treatment of an animal afflicted with
onychomycosis comprises an aryloxy derivative (I), a copper
composition, a peroxide, a polyhydroxy aromatic compound and a transition
metal coordination composition all admixed in a hydrophylllic carrier
composition.
DETAILED DESCRIPTION - Composition (C) for treatment of an animal
afflicted with **onychomycosis** comprises an aryloxy derivative of
formula (I), a copper composition, a peroxide, a polyhydroxy aromatic

compound and a transition metal coordination composition all admixed in a hydrophylllic carrier composition.

R1 = H, alkyl, hetero, heteroalkyl, aryl or heteroaryl;
 R3 = OH, alkyl, hetero, heteroalkyl, aryl or heteroaryl;
 R2 = hetero; and
 r7 = H, alkyl, hetero, heteroalkyl, aryl or heteroaryl.

An INDEPENDENT CLAIM is also included for preventing white line disease by applying (C) and a barrier composition (b) to the site of treatment.

ACTIVITY - Fungicide.

MECHANISM OF ACTION - None given.

USE - (C) is useful to treat onychomycosis and to treat/prevent whiteline disease (claimed). No details of tests for treating onychomycosis are given.

Dwg.0/0

FS CPI

FA AB; GI; DCN

MC CPI: A12-V; B05-A03A; B05-C08; B07-H; B10-C01; B10-C03; B10-E02; B10-F02; B10-H01; B14-A04; C05-A03A; C05-C08; C07-H; C10-C01; C10-C03; C10-E02; C10-F02; C10-H01; C14-A04

L10 ANSWER 2 OF 2 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN

AN 2004-106341 [11] WPIX

CR 2004-439503 [41]

DNC C2004-043070

TI Fungal infection treatment composition for treating, e.g. onychomycosis in animals, includes salicylate compound, copper composition, peroxide, polyhydric aromatic compound, and transition metal coordination complex.

DC C01

IN TARRET, B J

PA (TARB-I) TARRET B J

CYC 1

PI US 6680073 B1 20040120 (200411)* 4 A01N059-20 <--

ADT US 6680073 B1 Provisional US 1999-128604P 19990408, US 2000-545486 20000410

PRAI US 1999-128604P 19990408; US 2000-545486 20000410

IC ICM A01N059-20

AB US 6680073 B UPAB: 20040629 NOVELTY - A fungal infection treatment composition comprises a salicylate compound (I), a copper composition, a peroxide, polyhydric aromatic compound, and a transition metal coordination complex.

DETAILED DESCRIPTION - A fungal infection treatment composition comprises a compound of formula (I), a copper composition, peroxide, polyhydric aromatic compound, or a transition metal coordination complex, all dissolved in water. It contains greater than 100 mg copper composition.

R2 = hetero (O, S or N).

An INDEPENDENT CLAIM is also included for a pharmaceutical composition for the topical treatment of onychomycosis comprising the composition and a carrier.

ACTIVITY - Fungicide.

MECHANISM OF ACTION - None given.

USE - For treatment of fungal infections, e.g. onychomycosis, sporotrichosis, hoof rot, jungle rot, pseudallescheria boydii, scopulariopsis, or athletes foot in warm blooded animals, e.g. human and horses.

ADVANTAGE - The invention solves the problem of treating a human afflicted with onychomycosis without surgery, and has unique properties relative to migration into the infected site.

Dwg.0/0

FS CPI

FA AB; GI; DCN

MC CPI: C05-A03; C05-C08; C10-A04; C10-C01; C10-C02; C10-D03; C10-E04; C14-A04

=> b home

FILE 'HOME' ENTERED AT 10:16:22 ON 21 JUL 2005

=>

L23 272 SEA ABB=ON PLU=ON MYCOSIS+NT/CT (L) ?ONYCH?
 E PEROXIDES/CT
 E E3+ALL
L24 QUE ABB=ON PLU=ON PEROXIDES+OLD, NT/CT
 E PEROXIDES, BIO/CT
L25 6655 SEA ABB=ON PLU=ON "PEROXIDES, BIOLOGICAL STUDIES"/CT
L26 2300 SEA ABB=ON PLU=ON ?ONYCH?
L27 29 SEA ABB=ON PLU=ON L15 AND (L22 OR L23 OR L26)
L28 1 SEA ABB=ON PLU=ON L27 AND L4
L29 28 SEA ABB=ON PLU=ON L27 NOT L28
L30 3 SEA ABB=ON PLU=ON L29 AND (L16 OR COPPER OR CUPR? OR CU)
L31 0 SEA ABB=ON PLU=ON L30 AND (L17 OR L18)
L32 0 SEA ABB=ON PLU=ON L30 AND (L19 OR L20 OR L21)
L33 0 SEA ABB=ON PLU=ON L30 AND (L24 OR L25)
L34 1 SEA ABB=ON PLU=ON L28 AND (L16 OR COPPER OR CUPR? OR CU OR
 L17 OR L18 OR L24 OR L25)
L35 3669 SEA ABB=ON PLU=ON L15 AND (L16 OR COPPER OR CUPR? OR CU OR
 L17 OR L18 OR L24 OR L25)
L36 6 SEA ABB=ON PLU=ON L35 AND (L22 OR L23 OR L26)
L37 6 SEA ABB=ON PLU=ON L30 OR L36
L38 1 SEA ABB=ON PLU=ON L37 AND L4
L39 5 SEA ABB=ON PLU=ON L37 NOT L38
L40 1 SEA ABB=ON PLU=ON L38 OR L28 OR L34

FILE 'USPATFULL, USPAT2' ENTERED AT 11:08:23 ON 21 JUL 2005

L41 7416 SEA ABB=ON PLU=ON L15
L42 16 SEA ABB=ON PLU=ON L41 AND ONYCH?/TI, IT, AB, CLM
 E TARBET B/AU
L43 33 SEA ABB=ON PLU=ON ("TARBET B"/AU OR "TARBET BRYON J"/AU OR
 "TARBET BYRON J"/AU)
L44 2 SEA ABB=ON PLU=ON L42 AND L43
L45 14 SEA ABB=ON PLU=ON L42 NOT L44
L46 0 SEA ABB=ON PLU=ON L41 AND (ANTIONYCH? OR ANTI? (1A) ONYCH?)/T
 I, IT, AB, CLM
 E COPPER/CT
 E E4+ALL
L47 3 SEA ABB=ON PLU=ON L45 AND (COPPER OR CU OR CUPR? OR TRANSITIO
 N (1A) METAL? (1A) COMPEX? OR PEROX? OR (POLYHYDROX? OR POLY
 (1A) (HYDROX? OR OL) OR POLYOL) (2A) AROMAT?)/TI, IT, AB, CLM

FILE 'HCAPLUS' ENTERED AT 11:14:13 ON 21 JUL 2005

L48 185 SEA ABB=ON PLU=ON L15 AND (POLYOL OR POLY(1A)OL)
L49 0 SEA ABB=ON PLU=ON L48 AND (L22 OR L23 OR L26)

=> b reg

FILE 'REGISTRY' ENTERED AT 11:17:01 ON 21 JUL 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 20 JUL 2005 HIGHEST RN 856285-74-0
DICTIONARY FILE UPDATES: 20 JUL 2005 HIGHEST RN 856285-74-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

*


* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *

Structure search iteration limits have been increased. See HELP SLIMITS for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> d que sta 114
'1L4' IS NOT VALID HERE
For an explanation, enter "HELP DISPLAY QUERY".

=> d que sta l14
L12 STR



```
VAR G1=o/s  
VAR G2=OH/CY/AK  
NODE ATTRIBUTES:  
CONNECT IS M1 RC AT    7  
DEFAULT MLEVEL IS ATOM  
DEFAULT ELEVEL IS LIMITED
```

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 10

STEREO ATTRIBUTES: NONE
L14 8205 SEA FILE=REGISTRY CSS FUL L12

100.0% PROCESSED 520380 ITERATIONS 8205 ANSWERS
SEARCH TIME: 00.00.06

=> b hcaps
FILE 'HCAPLUS' ENTERED AT 11:17:22 ON 21 JUL 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing

=> d his full

(FILE 'HOME' ENTERED AT 10:11:44 ON 21 JUL 2005)

FILE 'HCAPLUS' ENTERED AT 10:12:00 ON 21 JUL 2005

L1 1 SEA ABB=ON PLU=ON (US2004096519 OR US6680073)/PN OR US99-1286
04#/AP, PRN
E TARBET B/AU
L2 59 SEA ABB=ON PLU=ON ("TARBET B J"/AU OR "TARBET BRIAN J"/AU OR
"TARBET BRYON J"/AU)
L3 1 SEA ABB=ON PLU=ON L2 AND ONYCHO?
L4 1 SEA ABB=ON PLU=ON L1 OR L3

FILE 'REGISTRY' ENTERED AT 10:14:30 ON 21 JUL 2005

FILE 'HCAPLUS' ENTERED AT 10:14:32 ON 21 JUL 2005
L5 TRA L4 1- RN : 10 TERMS

FILE 'REGISTRY' ENTERED AT 10:14:32 ON 21 JUL 2005
L6 10 SEA ABB=ON PLU=ON L5

FILE 'WPIX' ENTERED AT 10:14:35 ON 21 JUL 2005

L7 2 SEA ABB=ON PLU=ON (US2004096519 OR US6680073)/PN OR US99-1286
04#/AP, PRN
E TARBET B/AU
L8 29 SEA ABB=ON PLU=ON ("TARBET B"/AU OR "TARBET B G"/AU OR
"TARBET B J"/AU)
L9 2 SEA ABB=ON PLU=ON L8 AND ONYCH?/BIX,BI,ABEX
L10 2 SEA ABB=ON PLU=ON L7 OR L9

FILE 'REGISTRY' ENTERED AT 10:39:47 ON 21 JUL 2005

L11 STR
L12 STR, L11
L13 31 SEA CSS SAM L12
L14 8205 SEA CSS FUL L12

FILE 'HCAPLUS' ENTERED AT 10:45:52 ON 21 JUL 2005
L15 58489 SEA ABB=ON PLU=ON L14

E COPPER/CT
E E3+ALL
E COPPER CONT/CT
E COPPER COM/CT
E E36+ALL
E COMPOUNDS/CT
E E3+ALL
E CHEMISTRY/CT
E E3+ALL

L16 QUE ABB=ON PLU=ON CHEMISTRY+NT/CT (L) (COPPER OR CUPR? OR CU)
E PEROXIDES/CT
E E3+ALL

E AROMATIC/CT
L17 12 SEA ABB=ON PLU=ON (AROMATIC (1A)COMPOUND#)/CW (L) (POLYHYDROX?
OR POLY(1A)HYDROX?)

L18 20 SEA ABB=ON PLU=ON AROMATIC/CW (L) (POLYHYDROX? OR POLY(1A)HYDR
OX?)
E TRANSITION METAL/CT
E TRANSITION METAL COMPLEX/CT
E E4+OLD, NT1

L19 QUE ABB=ON PLU=ON (TRANSITION (1A)METAL?(1A) COMPLEX?)/CW

L20 25942 SEA ABB=ON PLU=ON TRANSITION METAL COMPLEXES+OLD/CT
QUE ABB=ON PLU=ON TRANSITION(1A) METAL?(1A) COMPLEX?

E NAIL (ANATOMICAL)/CT
E E3+ALL

L22 302 SEA ABB=ON PLU=ON "NAIL (ANATOMICAL)" +OLD/CT (L) ?ONYCH?
E MYCOSIS/CT
E E3+ALL

Nail (anatomical), disease
 (onychomycosis; solns. for treatment of onychomycosis
 in animals)

IT Equus caballus
 Human
 Mycosis
 (solns. for treatment of onychomycosis in animals)

IT Borates
 Peroxides, biological studies
 Transition metal complexes
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (solns. for treatment of onychomycosis in animals)

IT 69-72-7, Salicylic acid, biological studies 69-72-7D,
 Salicylic acid, derivs. 636-32-8, 1,2,4,5-Tetrahydroxybenzene
 7439-89-6D, Iron, complexes 7440-48-4D, Cobalt, complexes 7440-50-8D,
 Copper, complexes 7440-66-6D, Zinc, complexes 7722-84-1
 , Hydrogen peroxide., biological studies 7758-98-7, Copper
 sulfate, biological studies 10043-35-3, Boric acid, biological studies
 26062-79-3, Polydadmac
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (solns. for treatment of onychomycosis in animals)

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD


RE

(1) Benignus; US 2457025 A 1948 HCPLUS
 (2) Bernstein; US 2809971 A 1957 HCPLUS
 (3) Gans; US 5648389 A 1997 HCPLUS
 (4) Grier; US 3297525 A 1967 HCPLUS
 (5) Howard; US 6099854 A 2000 HCPLUS
 (6) Leebbrick; US 3287210 A 1966 HCPLUS
 (7) McFadden; US 3228830 A 1966 HCPLUS
 (8) Patterson; US 2066363 A 1937 HCPLUS
 (9) Yeaser; US 3288674 A 1966 HCPLUS

IT 69-72-7, Salicylic acid, biological studies
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (solns. for treatment of onychomycosis in animals)

RN 69-72-7 HCPLUS

CN Benzoic acid, 2-hydroxy- (9CI) (CA INDEX NAME)



=> d all hitstr 139 tot

L39 ANSWER 1 OF 5 HCPLUS COPYRIGHT 2005 ACS on STN
 AN 2004:569681 HCPLUS
 DN 141:117191
 ED Entered STN: 16 Jul 2004
 TI Seborrheic keratosis treatment using hydrogen peroxide
 IN Ancira, Margaret; Miller, Mickey
 PA USA
 SO U.S. Pat. Appl. Publ., 17 pp., Cont.-in-part of U.S. Ser. No. 72,829.
 CODEN: USXXCO
 DT Patent
 LA English
 IC ICM A61K033-40
 INCL 424616000; 514474000; 514561000; 514276000; 514250000; 514356000
 CC 1-12 (Pharmacology)
 Section cross-reference(s): 63
 FAN.CNT 2
 PATENT NO. KIND DATE APPLICATION NO. DATE

PI	US 2004137077	A1	20040715	US 2003-684136	20031009
	US 2003008018	A1	20030109	US 2002-72829	20020208
PRAI	US 2001-267978P	P	20010209		
	US 2002-72829	A2	20020208		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES			
US 2004137077	ICM	A61K033-40			
	INCL	424616000; 514474000; 514561000; 514276000; 514250000; 514356000			
US 2004137077	NCL	424/616.000; 514/474.000; 514/561.000; 514/276.000; 514/250.000; 514/356.000			
	ECLA	A61K008/33; A61K033/40; A61K033/40+M			
US 2003008018	NCL	424/616.000; 514/474.000; 514/251.000; 514/356.000; 514/276.000			
	ECLA	A61K008/33; A61K033/40; A61K033/40+M			

AB The subject of the present invention is seborrheic keratosis removal and prevention utilizing safe dependable effective biocompatible treatments with no scarring, bleeding, burning, freezing, shocking, and hypopigmentation or hyperpigmentation. Seborrheic keratoses are removed by: (a) obtaining a composition comprising hydrogen peroxide in a concentration of at least about 23 %; and (b) applying the composition to a seborrheic keratosis on a seborrheic keratoses afflicted person or domesticated animal. Patients were treated with applications of 35 % hydrogen peroxide. Compns. are presented.

ST seborrheic keratosis removal hydrogen peroxide

IT Keratosis

(actinic, treatment of; seborrheic keratosis treatment using hydrogen peroxide)

IT Infection

Reproductive tract, neoplasm

(acuminate wart, treatment of; seborrheic keratosis treatment using hydrogen peroxide)

IT Wart

(acuminate, genital, treatment of; seborrheic keratosis treatment using hydrogen peroxide)

IT Skin, disease

(aging, rhytides, treatment of; seborrheic keratosis treatment using hydrogen peroxide)

IT Quaternary ammonium compounds, biological studies

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(alkylbenzyldimethyl, chlorides, as surfactant, composition further containing; seborrheic keratosis treatment using hydrogen peroxide)

IT Brushes

Injectors

Pipets

Spray atomizers

Spraying apparatus
(application using; seborrheic keratosis treatment using hydrogen peroxide)

IT Rumex crispus

(as melanin inhibitor, composition further containing; seborrheic keratosis treatment using hydrogen peroxide)

IT Glycosides

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(as melanin inhibitor, composition further containing; seborrheic keratosis treatment using hydrogen peroxide)

IT Lecithins

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(as surfactant, composition further containing; seborrheic keratosis treatment using hydrogen peroxide)

IT Cananga odorata

Chenopodium
 Eucalyptus
 Pimpinella anisum
 (as terpene, composition further containing; seborrheic keratosis treatment using hydrogen peroxide)
 IT Skin, neoplasm
 (basal cell carcinoma, treatment of; seborrheic keratosis treatment using hydrogen peroxide)
 IT Carcinoma
 (basal cell, treatment of; seborrheic keratosis treatment using hydrogen peroxide)
 IT Fats and Glyceridic oils, biological studies
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (borage seed, as γ -linolenic precursor, composition further containing; seborrheic keratosis treatment using hydrogen peroxide)
 IT Skin, disease
 (clear cell acanthoma, treatment of; seborrheic keratosis treatment using hydrogen peroxide)
 IT Melanins
 RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)
 (composition containing inhibitor of; seborrheic keratosis treatment using hydrogen peroxide)
 IT Aloe barbadensis
 Surfactants
 Witch hazel
 (composition further containing; seborrheic keratosis treatment using hydrogen peroxide)
 IT Alcohols, biological studies
 Amides, biological studies
 Estrogens
 Fatty acids, biological studies
 Hormones, animal, biological studies
 Ketones, biological studies
 Polyoxyalkylenes, biological studies
 Sulfoxides
 Terpenes, biological studies
 Thymus hormones
 Thyroid hormones
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (composition further containing; seborrheic keratosis treatment using hydrogen peroxide)
 IT Protein hydrolyzates
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (conchiolin hydrolyzates, as melanin inhibitor, composition further containing; seborrheic keratosis treatment using hydrogen peroxide)
 IT Albuminoids
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (conchiolins, hydrolyzates, as melanin inhibitor, composition further containing; seborrheic keratosis treatment using hydrogen peroxide)
 IT Skin, disease
 (corn, treatment of; seborrheic keratosis treatment using hydrogen peroxide)
 IT Fats and Glyceridic oils, biological studies
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (currant, Ribes nigrum seed, as γ -linolenic precursor, composition further containing; seborrheic keratosis treatment using hydrogen peroxide)
 IT Carcinoma
 (cutaneous squamous cell, treatment of; seborrheic keratosis treatment using hydrogen peroxide)
 IT Papilloma

(cutaneous, treatment of; seborrheic keratosis treatment using hydrogen peroxide)

IT Medical goods
 (droppers, application using; seborrheic keratosis treatment using hydrogen peroxide)

IT Fatty acids, biological studies
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (esters, composition further containing; seborrheic keratosis treatment using hydrogen peroxide)

IT Fats and Glyceridic oils, biological studies
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (evening primrose, as γ -linolenic precursor, composition further containing; seborrheic keratosis treatment using hydrogen peroxide)

IT Arctostaphylos uva-ursi
 Haematoxylon campechianum
 Vaccinium myrtillus
 (extract, as melanin inhibitor, composition further containing; seborrheic keratosis treatment using hydrogen peroxide)

IT Skin, disease
 (fibroepithelial polyps, treatment of; seborrheic keratosis treatment using hydrogen peroxide)

IT Infection
 Skin, disease
 (herpes, treatment of; seborrheic keratosis treatment using hydrogen peroxide)

IT Skin, disease
 (hyperpigmentation, treatment of; seborrheic keratosis treatment using hydrogen peroxide)

IT Keratosis
 (inverted follicular keratosis, treatment of; seborrheic keratosis treatment using hydrogen peroxide)

IT Natural products, pharmaceutical
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (licorice, as melanin inhibitor, composition further containing; seborrheic keratosis treatment using hydrogen peroxide)

IT Mycosis
 Nail (anatomical), disease
 (onychomycosis, treatment of; seborrheic keratosis treatment using hydrogen peroxide)

IT Acids, biological studies
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (organic, composition further containing; seborrheic keratosis treatment using hydrogen peroxide)

IT Skin, neoplasm
 (papilloma, treatment of; seborrheic keratosis treatment using hydrogen peroxide)

IT Drug delivery systems
 (patches, application using; seborrheic keratosis treatment using hydrogen peroxide)

IT Alcohols, biological studies
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (polyhydric, composition further containing; seborrheic keratosis treatment using hydrogen peroxide)

IT Phenols, biological studies
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (polyphenols, nonpolymeric, as melanin inhibitor, composition further containing; seborrheic keratosis treatment using hydrogen peroxide)

IT Pruritus
 (prurigo nodularis, treatment of; seborrheic keratosis treatment using hydrogen peroxide)

IT Pueraria
 (root, as melanin inhibitor, composition further containing; seborrheic keratosis treatment using hydrogen peroxide)

IT Skin, disease
 (rosacea, treatment of; seborrheic keratosis treatment using hydrogen peroxide)

IT Domestic animal
 Human
 (seborrheic keratosis treatment using hydrogen peroxide)

IT Peroxides, biological studies
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (seborrheic keratosis treatment using hydrogen peroxide)

IT Amino acids, biological studies
 Vitamins
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (seborrheic keratosis treatment using hydrogen peroxide)

IT Keratosis
 (seborrheic; seborrheic keratosis treatment using hydrogen peroxide)

IT Lithospermum
 (seed extract, as melanin inhibitor, composition further containing; seborrheic keratosis treatment using hydrogen peroxide)

IT Skin, neoplasm
 Skin, neoplasm
 (squamous cell carcinoma, treatment of; seborrheic keratosis treatment using hydrogen peroxide)

IT Carcinoma
 (squamous cell, treatment of; seborrheic keratosis treatment using hydrogen peroxide)

IT Foot
 (toe, disease, corn, treatment of; seborrheic keratosis treatment using hydrogen peroxide)

IT Acne
 Melanoma
 Psoriasis
 Wart
 (treatment of; seborrheic keratosis treatment using hydrogen peroxide)

IT Skin, disease
 (warty dyskeratosis, treatment of; seborrheic keratosis treatment using hydrogen peroxide)

IT 53-86-1D, Indomethacin, derivs. 60-33-3, Linoleic acid, biological studies 69-72-7D, Salicylic acid, alkyl derivs. 79-09-4, Propionic acid, biological studies 83-86-3, Phytic acid 98-92-0, Niacinamide 108-95-2, Phenol, biological studies 123-31-9, Hydroquinone, biological studies 123-31-9D, Hydroquinone, glycosides 123-99-9, Azelaic acid, biological studies 137-66-6, Ascorbyl palmitate 288-47-1D, Thiazole, compds. 331-39-5, Caffeic acid 461-72-3, Hydantoin 476-66-4, Ellagic acid 491-38-3D, Chromone, derivs. 497-76-7, Arbutin 501-30-4, Kojic acid 501-30-4D, Kojic acid, dimer 501-30-4D, Kojic acid, glycosides 621-82-9, Cinnamic acid, biological studies 636-58-8 1182-34-9, Dicaffeoylquinic acid 1197-18-8, Tranexamic acid 1405-86-3, Glycyrrhizic acid 7704-34-9, Sulfur, biological studies 9012-76-4, Chitosan 9054-89-1, Superoxide dismutase 9083-38-9, Melanostatin 12001-79-5, Vitamin K 25138-66-3, S-Lactoyl glutathione 27025-41-8, Oxidized glutathione 37299-36-8, Lavanol 56328-22-4 86632-03-3 108910-78-7, Magnesium ascorbyl phosphate
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (as melanin inhibitor, composition further containing; seborrheic keratosis treatment using hydrogen peroxide)

IT 57-09-0, Cetyltrimethylammonium bromide 112-00-5, Dodecyltrimethylammonium chloride 112-02-7, Hexadecyltrimethylammonium chloride 112-03-8, Octadecyltrimethylammonium chloride 123-03-5, Cetylpyridinium chloride 145-42-6, Sodium taurocholate 151-21-3, Sodium lauryl sulfate, biological studies 302-95-4, Sodium desoxycholate

361-09-1, Sodium cholate 629-25-4, Sodium laurate 1119-97-7,
 Tetradecyltrimethylammonium bromide 1338-39-2, Span 20 1338-41-6, Span
 60 1338-43-8, Span 80 2836-32-0, Sodium glycolate 9002-92-0, Brij 30
 9004-98-2, Brij 93 9004-99-3, Myrj 45 26266-57-9, Span 40
 77466-09-2, Miglyol 840 106392-12-5, Poloxamer 231
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (as surfactant, composition further containing; seborrheic keratosis treatment
 using hydrogen peroxide)

IT 80-56-8, α -Pinene 89-80-5, Menthone 89-81-6, Piperitone
 89-82-7, Pulegone 98-55-5, α -Terpineol 99-48-9, Carveol
 99-49-0, Carvone 285-67-6, Cyclopentene oxide 286-20-4, Cyclohexene
 oxide 470-82-6, 1,8-Cineole 554-60-9, β -Carene 562-74-3,
 Terpinen-4-ol 1195-92-2, Limonene oxide 1686-14-2, α -Pinene
 oxide 5989-27-5, D-Limonene
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (as terpene, composition further containing; seborrheic keratosis treatment
 using hydrogen peroxide)

IT 9002-72-6, Growth hormone
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (composition further containing human; seborrheic keratosis treatment using
 hydrogen peroxide)

IT 506-26-3, Gamma linolenic acid
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (composition further containing precursor for; seborrheic keratosis treatment
 using hydrogen peroxide)

IT 50-21-5, Lactic acid, biological studies 53-43-0, Dehydroepiandrosterone
 56-81-5, Glycerol, biological studies 57-11-4, Stearic acid, biological
 studies 57-13-6, Urea, biological studies 57-55-6, Propylene glycol,
 biological studies 57-83-0, Progesterone, biological studies 58-22-0,
 Testosterone 64-17-5, Ethanol, biological studies 67-68-5, Dimethyl
 sulfoxide, biological studies 67-71-0, Methylsulfonylmethane 68-12-2,
 Dimethylformamide, biological studies 69-72-7, Salicylic acid,
 biological studies 71-23-8, Propanol, biological studies 71-36-3,
 Butanol, biological studies 71-41-0, Pentanol, biological studies
 73-31-4, Melatonin 77-92-9, Citric acid, biological studies 78-92-2,
 2-Butanol 79-14-1, Glycolic acid, biological studies 79-20-9, Methyl
 acetate 79-33-4, L-Lactic acid, biological studies 80-69-3, Tartronic
 acid 87-69-4, Tartaric acid, biological studies 87-73-0, Saccharic
 acid 90-64-2, Mandelic acid 100-51-6, Benzyl alcohol, biological
 studies 102-71-6, Triethanolamine, biological studies 107-21-1,
 Ethylene glycol, biological studies 109-52-4, Valeric acid, biological
 studies 110-15-6, Succinic acid, biological studies 110-27-0,
 Isopropyl myristate 110-40-7, Diethyl sebacate 111-14-8, Heptanoic
 acid 111-27-3, Hexanol, biological studies 111-42-2, Diethanolamine,
 biological studies 111-46-6, Diethylene glycol, biological studies
 111-62-6, Ethyl oleate 111-65-9, N-Octane, biological studies
 111-84-2, N-Nonane 111-87-5, Octanol, biological studies 112-05-0,
 Pelargonic acid 112-27-6, Triethylene glycol 112-30-1, Decanol
 112-40-3, N-Dodecane 112-80-1, Oleic acid, biological studies
 123-86-4, Butyl acetate 124-07-2, Caprylic acid, biological studies
 124-18-5, N-Decane 127-17-3, Pyruvic acid, biological studies
 127-19-5, Dimethylacetamide 134-62-3, Diethyltoluamide 141-78-6, Ethyl
 acetate, biological studies 142-62-1, Caproic acid, biological studies
 142-82-5, N-Heptane, biological studies 142-91-6, Isopropyl palmitate
 143-07-7, Lauric acid, biological studies 143-08-8, Nonanol 145-13-1,
 Pregnenolone 156-06-9, β -Phenylpyruvic acid 320-77-4, Isocitric
 acid 334-48-5, Capric acid 433-48-7, β -Fluoropyruvic acid
 473-81-4, Glyceric acid 497-76-7D, Arbutin, isomers 515-30-0,
 Atrolactic acid 526-95-4, Gluconic acid 526-99-8, Mucic acid
 544-63-8, Myristic acid, biological studies 544-76-3, N-Hexadecane
 554-12-1, Methyl propionate 594-61-6, 2-Hydroxyisobutyric acid
 600-15-7, α -Hydroxybutyric acid 624-24-8, Methyl valerate

629-50-5, N-Tridecane 629-59-4, N-Tetradecane 685-73-4, Galacturonic acid 828-01-3, β -Phenyllactic acid 1118-92-9 1120-21-4, N-Undecane 3079-28-5, Decyl methyl sulfoxide 3402-98-0, Iduronic acid 3416-24-8, Glucosamine 5699-58-1, Acetylpyruvic acid 6032-29-7, 2-Pentanol 6556-12-3, Glucuronic acid 6703-05-5, Lyxaric acid 6814-36-4, Mannuronic acid 6915-15-7, Malic acid 10158-64-2, Xylaric acid 14433-76-2 15769-56-9, Guluronic acid 18494-60-5 23351-51-1, Glucoheptonic acid 24871-35-0, Altronic acid 25265-71-8, Dipropylene glycol 25322-68-3, Polyethylene glycol 28223-51-0, Alluronic acid 28223-52-1, Taluronic acid 30923-19-4, Lyxuronic acid 30923-20-7, Riburonic acid 30923-21-8, Xyluronic acid 30923-39-8, Arabinuronic acid 36413-60-2, Quinic acid 66664-08-2, Pentahydroxyhexanoic acid 83826-43-1, Octyldodecyl myristate 84710-55-4, Threuric acid 84710-56-5, Erythreuric acid 474655-00-0 722493-20-1
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (composition further containing; seborrheic keratosis treatment using hydrogen peroxide)


IT 94-36-0, Benzoyl peroxide, biological studies 7722-84-1,
 Hydrogen peroxide, biological studies
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (seborrheic keratosis treatment using hydrogen peroxide)

IT 50-81-7, Ascorbic acid, biological studies 52-90-4, L-Cysteine, biological studies 56-40-6, Glycine, biological studies 56-41-7, L-Alanine, biological studies 56-45-1, L-Serine, biological studies 56-85-9, L-Glutamine, biological studies 56-87-1, L-Lysine, biological studies 56-89-3, L-Cystine, biological studies 59-43-8, Thiamin, biological studies 59-67-6, Niacin, biological studies 60-18-4, L-Tyrosine, biological studies 61-90-5, L-Leucine, biological studies 63-68-3, L-Methionine, biological studies 63-91-2, L-Phenylalanine, biological studies 70-26-8, L-Ornithine 70-47-3, L-Asparagine, biological studies 71-00-1, L-Histidine, biological studies 72-18-4, L-Valine, biological studies 72-19-5, L-Threonine, biological studies 73-22-3, L-Tryptophan, biological studies 73-32-5, L-Isoleucine, biological studies 74-79-3, L-Arginine, biological studies 83-88-5, Riboflavin, biological studies 147-85-3, L-Proline, biological studies 305-84-0, Carnosine 541-15-1, L-Carnitine 1190-94-9, 5-Hydroxylysine
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (seborrheic keratosis treatment using hydrogen peroxide)

IT 79-17-4, Aminoguanidine 7732-18-5, Water, biological studies 9067-32-7, Sodium hyaluronate
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (seborrheic keratosis treatment using hydrogen peroxide)

IT 69-72-7D, Salicylic acid, alkyl derivs.
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (as melanin inhibitor, composition further containing; seborrheic keratosis treatment using hydrogen peroxide)


RN 69-72-7 HCAPLUS
 CN Benzoic acid, 2-hydroxy- (9CI) (CA INDEX NAME)




IT 69-72-7, Salicylic acid, biological studies
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (composition further containing; seborrheic keratosis treatment using hydrogen peroxide)

RN 69-72-7 HCAPLUS

CN Benzoic acid, 2-hydroxy- (9CI) (CA INDEX NAME)



IT 94-36-0, Benzoyl peroxide, biological studies 7722-84-1,
Hydrogen peroxide, biological studies
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);
THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(seborrheic keratosis treatment using hydrogen peroxide)
RN 94-36-0 HCPLUS
CN Peroxide, dibenzoyl (9CI) (CA INDEX NAME)



RN 7722-84-1 HCPLUS
CN Hydrogen peroxide (H2O2) (9CI) (CA INDEX NAME)

HO—OH

L39 ANSWER 2 OF 5 HCPLUS COPYRIGHT 2005 ACS on STN
 AN 2002:391479 HCPLUS
 DN 136:390755
 ED Entered STN: 24 May 2002
 TI Antifungal nail composition containing a copper salt
 IN Zeiler, Kenneth T.
 PA USA
 SO PCT Int. Appl., 23 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K007-04
 ICS A61K033-34
 CC 62-4 (Essential Oils and Cosmetics)
 Section cross-reference(s): 1, 63

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002039963	A1	20020523	WO 2001-US29438	20010919
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2431651	AA	20020523	CA 2001-2431651	20010919
	AU 2001092866	A5	20020527	AU 2001-92866	20010919
	EP 1341500	A1	20030910	EP 2001-973268	20010919
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004513905	T2	20040513	JP 2002-542338	20010919
	US 2004001791	A1	20040101	US 2003-440468	20030516

PRAI US 2000-249381P	P	20001116
US 2001-286781P	P	20010426
WO 2001-US29438	W	20010919
US 2002-421257P	P	20021025

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
------------	-------	------------------------------------

WO 2002039963	ICM	A61K007-04
	ICS	A61K033-34
WO 2002039963	ECLA	A61K007/04D; A61K031/28; A61K033/34
JP 2004513905	FTERM	4C076/AA11; 4C076/AA94; 4C076/BB31; 4C076/CC20; 4C076/CC31; 4C076/FF31; 4C083/AB101; 4C083/AB211; 4C083/AB311; 4C083/AB351; 4C083/AB352; 4C083/AC271; 4C083/AC301; 4C083/AC311; 4C083/AC471; 4C083/AC931; 4C083/CC28; 4C083/DD23; 4C083/DD27; 4C083/EE50; 4C086/AA01; 4C086/AA02; 4C086/BC28; 4C086/DA17; 4C086/HA01; 4C086/HA21; 4C086/HA24; 4C086/HA26; 4C086/HA28; 4C086/MA01; 4C086/MA17; 4C086/MA63; 4C086/ZA90; 4C086/ZB35; 4C206/AA01; 4C206/AA02; 4C206/DA07; 4C206/DA13; 4C206/DA19; 4C206/JB01; 4C206/MA01; 4C206/MA37; 4C206/MA83; 4C206/NA12; 4C206/ZA90; 4C206/ZB35
US 2004001791	NCL	424/061.000; 424/637.000
	ECLA	A61K031/30; A61K033/34

- AB A method for treating **onychomycosis** in humans comprises contacting a fungi-infected nail with a composition comprising an effective amount of a **copper salt**. Most preferably, the fungi-infected nail is treated with 10% (weight/weight) aqueous copper(II) sulfate. The nail composition released **copper salt** over time in a controlled-release fashion. Treating human nails with the **copper salt** composition can be used to detect fungal infection before routine phys. symptoms are presented due to staining of fungi-infected human nail tissue by a **copper salt**. Fungal infection is also prevented by pre-treatment of nails with the **copper salt** composition
- ST **copper salt controlled release antifungal nail cosmetic**
IT **Fungicides**
IT **Human**
 (**antifungal nail composition containing copper salts**)
IT **Acrylic polymers, biological studies**
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
 (**antifungal nail composition containing copper salts**)
IT **Nail (anatomical)**
 (**artificial; antifungal nail composition containing copper salts**)
IT **Drug delivery systems**
 (**controlled-release, topical; antifungal nail composition containing copper salts**)
IT **Naphthenic acids, biological studies**
RL: COS (Cosmetic use); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (**copper salts; antifungal nail composition containing copper salts**)
IT **Hand**
Nail (anatomical)
 (**fingernail; antifungal nail composition containing copper salts**)
IT **Cosmetics**
 (**gels; antifungal nail composition containing copper salts**)
IT **Cosmetics**
 (**nail lacquers; antifungal nail composition containing copper salts**)
IT **Mycosis**
 Nail (anatomical), disease
 (**onychomycosis; antifungal nail composition containing copper salts**)
IT **Foot**
Nail (anatomical)
 (**toenail; antifungal nail composition containing copper salts**)
IT 527-09-3, **Copper gluconate** 1344-70-3, **Copper oxide**

4180-12-5, Copper acetate 7440-50-8D, Copper,
 ammonium complexes and salts 7492-68-4, Copper carbonate
 7758-98-7, Copper sulfate, biological studies 16039-52-4,
 Copper lactate 16048-96-7, Copper(II)
 salicylate 18970-62-2 27004-40-6, Copper tartrate
 40974-00-3, Copper perchlorate 70027-50-8, Copper
 selenate
 RL: COS (Cosmetic use); PAC (Pharmacological activity); THU (Therapeutic
 use); BIOL (Biological study); USES (Uses)
 (antifungal nail composition containing copper salts)

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD


RE

- (1) Aquanautics Corp; WO 9311735 A 1993 HCPLUS
- (2) Aron, R; US 3257280 A 1966 HCPLUS
- (3) Butler, H; MEDICAL JOURNAL OF AUSTRALIA 1970, V2, P309 MEDLINE
- (4) Corliss, L; US 4822595 A 1989 HCPLUS
- (5) Fitolon Co Ltd; RU 2063744 C 1996 HCPLUS
- (6) Intr Prod Cosmetice Miraj; RO 88114 A 1985
- (7) Passarelli, M; US 4933175 A 1990
- (8) Scivoletto, R; WO 9852927 A 1998 HCPLUS

IT 16048-96-7, Copper(II) salicylate
 RL: COS (Cosmetic use); PAC (Pharmacological activity); THU (Therapeutic
 use); BIOL (Biological study); USES (Uses)
 (antifungal nail composition containing copper salts)

RN 16048-96-7 HCPLUS

CN Copper, bis[2-(hydroxy- κ O)benzoato- κ O]- (9CI) (CA INDEX NAME)



L39 ANSWER 3 OF 5 HCPLUS COPYRIGHT 2005 ACS on STN
 AN 2002:353986 HCPLUS
 DN 136:359653
 ED Entered STN: 12 May 2002
 TI Pharmaceutical compositions for managing skin conditions
 IN Murad, Howard
 PA USA
 SO U.S. Pat. Appl. Publ., 19 pp., Cont.-in-part of U.S. 878,231.
 CODEN: USXXCO
 DT Patent
 LA English
 IC ICM A61K033-40
 ICS A61K035-78
 INCL 424616000
 CC 63-6 (Pharmaceuticals)

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002054918	A1	20020509	US 2001-953431	20010917
	US 6673374	B2	20040106		
	US 2002041901	A1	20020411	US 2001-878231	20010612
	US 6383523 ✓	B1	20020507		
	US 2003007939 ✓	A1	20030109	US 2002-77928	20020220

US 2004091548	A1	20040513	US 2003-702453	20031107
PRAI US 2001-878231	A2	20010612		
US 1998-94775P	P	19980731		
US 1999-330127	A2	19990611		
US 2000-549202	A1	20000413		
US 2001-953431	A2	20010917		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2002054918	ICM	A61K033-40
	ICS	A61K035-78
	INCL	424616000
US 2002054918	NCL	424/616.000; 514/248.000; 514/616.000; 514/714.000; 514/739.000
	ECLA	A61K008/22; A61K033/40+M; A61K045/06; A61Q019/00
US 2002041901	NCL	424/616.000; 514/396.000; 514/557.000; 514/568.000; 514/574.000; 514/739.000
	ECLA	A61K008/22; A61K008/365; A61K008/60A; A61K008/97; A61K033/40+M; A61K045/06; A61Q019/00; C11D003/00B13; C11D003/20E5
US 2003007939	NCL	424/061.000; 424/070.100; 424/616.000
	ECLA	A61K008/22; C11D003/20E5; A61K008/365; A61K008/60A; A61K008/97; A61K033/40+M; A61K045/06; A61Q019/00; C11D003/00B13
US 2004091548	NCL	424/616.000
	ECLA	A61K008/22; A61K008/365; A61K008/60A; A61K008/97; A61K033/40+M; A61K045/06; A61Q019/00; C11D003/00B13; C11D003/20E5

AB This application relates to a pharmaceutical composition and methods for treating inflammatory skin conditions. The compns. include hydrogen peroxide, 1 or more moisturizing agents, and an anti-inflammatory agent. The pharmaceutical compns. may optionally include 1 or more exfoliants. The compns. can be used to treat inflammatory skin conditions such as dermatitis, including, but not limited to seborheic dermatitis, nummular dermatitis, contact dermatitis, atopic dermatitis, exfoliative dermatitis, and stasis dermatitis; psoriasis; folliculitis; rosacea; acne; impetigo; erysipelas; paronychia, erythrasma; and eczema. A skin cleanser formulation contained water 49.2, trisodium EDTA 10, Mackanate EL 17, Monateric CDX-38 11, Crothix 1.5, Kessco PEG-6000 DS 0.7, methylparaben 0.2, salicylic acid 1.6, citric acid 1.5, Irgasan DP-300 0.3, Solibilisant LR1 2, fragrance 0.3, menthol 0.1, butylene glycol 0.1, Snakeroot BG50 0.1, Ajidew-50 0.2, Phospholipid PTC 1, and 35% H2O2 solution 3%.

ST pharmaceutical hydrogen peroxide skin disorder

IT Surfactants

(amphoteric; pharmaceutical compns. for managing skin conditions)

IT Dermatitis

(atopic; pharmaceutical compns. for managing skin conditions)

IT Fats and Glyceridic oils, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(borage seed; pharmaceutical compns. for managing skin conditions)

IT Cosmetics

(cleansing; pharmaceutical compns. for managing skin conditions)

IT Skin, disease

(erysipelas; pharmaceutical compns. for managing skin conditions)

IT Skin, disease

(erythrasma; pharmaceutical compns. for managing skin conditions)

IT Fats and Glyceridic oils, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(fish, n-3 fatty acid-high; pharmaceutical compns. for managing skin conditions)

IT Fats and Glyceridic oils, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(fish, n-6 fatty acid-high; pharmaceutical compns. for managing skin conditions)

IT Hair

(folliculitis; pharmaceutical compns. for managing skin conditions)

IT Carboxylic acids, biological studies
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (hydroxy; pharmaceutical compns. for managing skin conditions)

IT Skin, disease
 (impetigo; pharmaceutical compns. for managing skin conditions)

IT Drug delivery systems
 (lotions; pharmaceutical compns. for managing skin conditions)

IT Cosmetics
 (moisturizers; pharmaceutical compns. for managing skin conditions)

IT Amino acids, biological studies
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (of keratin; pharmaceutical compns. for managing skin conditions)

IT Acne
 Analgesics
 Anesthetics
 Anti-inflammatory agents
 Antibacterial agents
 Antioxidants
 Dermatitis
 Eczema
 Fungicides
 Paronychia
 Preservatives
 Psoriasis
 Seborrhea
 Skin preparations (pharmaceutical)
 Stabilizing agents
 (pharmaceutical compns. for managing skin conditions)

IT Ceramides
 Keratins
 Linseed oil
 Tannins
 Tocopherols
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (pharmaceutical compns. for managing skin conditions)

IT Fats and Glyceridic oils, biological studies
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (primrose; pharmaceutical compns. for managing skin conditions)

IT Skin, disease
 (rosacea; pharmaceutical compns. for managing skin conditions)

IT Drug delivery systems
 (topical; pharmaceutical compns. for managing skin conditions)

IT Proteins
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (wheat; pharmaceutical compns. for managing skin conditions)

IT 7722-84-1, Hydrogen peroxide, biological studies
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (pharmaceutical compns. for managing skin conditions)

IT 50-21-5, Lactic acid, biological studies 50-78-2, Aspirin
 56-81-5, Glycerin, biological studies 60-33-3, Linoleic acid, biological
 studies 69-72-7, Salicylic acid, biological studies 77-92-9,
 Citric acid, biological studies 79-14-1, Glycolic acid, biological
 studies 81-13-0, Panthenol 9004-61-9, Hyaluronic acid 9006-65-9,
 Dimethicone 15687-27-1, Ibuprofen 22071-15-4, Ketoprofen 22204-53-1,
 Naproxen 28874-51-3 51744-92-4
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (pharmaceutical compns. for managing skin conditions)

RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) af Ekenstam; US 4557935 A 1985 HCPLUS
- (2) Anon; GB 1135643 1968 HCPLUS
- (3) Anon; GB 2076286 1981 HCPLUS
- (4) Anon; CA 1174976 1984 HCPLUS
- (5) Anon; EP 0191214 1986 HCPLUS
- (6) Anon; GB 2189394 1987 HCPLUS

- (7) Anon; EP 2250539 1991
 (8) Anon; EP 0425507 1995
 (9) Bansemir; US 4900721 A 1990 HCPLUS
 (10) Barton; US 5695745 A 1997 HCPLUS
 (11) Bekele; US 6495150 B2 2002 HCPLUS
 (12) Bowing; US 4051058 A 1977 HCPLUS
 (13) Bowing; US 4051059 A 1977 HCPLUS
 (14) Burke; US 5296215 A 1994 HCPLUS
 (15) Burke; US 5693318 A 1997
 (16) Claeys; US 4203765 A 1980
 (17) Coats; US 4178372 A 1979 HCPLUS
 (18) Cook; US 5008030 A 1991 HCPLUS
 (19) De Grandis; Rib. ital. Essenze 1974, V56(7), P371 HCPLUS
 (20) Devillez; US 5958984 A 1999 HCPLUS
 (21) Dresdner; US 5357636 A 1994
 (22) Gallina; US 4514384 A 1985 HCPLUS
 (23) Ganci; US 4438102 A 1984 HCPLUS
 (24) Greene; US 4557898 A 1985 HCPLUS
 (25) Hall; US 5547990 A 1996 HCPLUS
 (26) Herb; US 6022547 A 2000 HCPLUS
 (27) Hopkins; US 4534945 A 1985 HCPLUS
 (28) Jarrett; US 5593952 A 1997 HCPLUS
 (29) Mills; vol. I 1982, V4, P233
 (30) Newell; US 3297456 A 1967 HCPLUS
 (31) Oliver; US 5869062 A 1999 HCPLUS
 (32) Robinson; US 5474768 A 1995 HCPLUS
 (33) Rovati; US 5177099 A 1993 HCPLUS
 (34) Sawaya; US 5519059 A 1996 HCPLUS
 (35) Schmidt; US 5139788 A 1992 HCPLUS
 (36) Scholz; US 5951993 A 1999 HCPLUS
 (37) Skiar; US 5861432 A 1999 HCPLUS
 (38) Smith; US 6491928 B1 2002 HCPLUS
 (39) Song; US 5843998 A 1998 HCPLUS
 (40) Wile; Current. Med. res. Opin. 1986, V10(2), P82 HCPLUS
 (41) Yu; US 5641475 A 1997 HCPLUS

IT 7722-84-1, Hydrogen peroxide, biological studies
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (pharmaceutical compns. for managing skin conditions)

RN 7722-84-1 HCPLUS


CN Hydrogen peroxide (H₂O₂) (9CI) (CA INDEX NAME)

HO—OH

IT 50-78-2, Aspirin 69-72-7, Salicylic acid, biological
 studies
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (pharmaceutical compns. for managing skin conditions)


RN 50-78-2 HCPLUS

CN Benzoic acid, 2-(acetyloxy)- (9CI) (CA INDEX NAME)



RN 69-72-7 HCPLUS

CN Benzoic acid, 2-hydroxy- (9CI) (CA INDEX NAME)



L39 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 1999:90501 HCAPLUS
 DN 130:150435
 ED Entered STN: 12 Feb 1999
 TI Phototherapy-based method and composition for treating pathogens
 IN Lurie, Raz
 PA Dermatolazer Technologies Ltd., Israel; Friedman, Mark, M.
 SO PCT Int. Appl., 37 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A01N025-00
 CC 8-9 (Radiation Biochemistry)
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9904628	A1	19990204	WO 1998-US14162	19980713
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2298526	AA	19990204	CA 1998-2298526	19980713
	AU 9884788	A1	19990216	AU 1998-84788	19980713
	AU 750933	B2	20020801		
	EP 1005267	A1	20000607	EP 1998-935571	19980713
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI				
	JP 2001510773	T2	20010807	JP 2000-503708	19980713
	US 6090788	A	20000718	US 1999-343199	19990630
PRAI	US 1997-901426	A	19970728		
	WO 1998-US14162	W	19980713		

CLASS

	PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
	WO 9904628	ICM	A01N025-00
	WO 9904628	ECLA	A61K041/00H6; A61N005/06C8
	US 6090788	NCL	514/023.000; 427/595.000; 427/596.000; 606/002.000; 606/003.000
		ECLA	A61K031/00+A; A61K031/352; A61K031/409

AB A method for treating an area of skin or nail affected with a pathogen comprises irradiating the area of skin or nail with a light beam having at least one wavelength absorbable by the pathogen.
 ST phototherapy skin nail pathogen
 IT Inks
 (India; phototherapy-based method and composition for treating pathogens)
 IT Spore
 (ascospore, stain; phototherapy-based method and composition for treating pathogens)
 IT Porphyrins
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (benzoporphyrins, derivative, monoacid; phototherapy-based method and composition for treating pathogens)
 IT Drugs
 (bioreductive; phototherapy-based method and composition for treating pathogens)

IT Inks
(black; phototherapy-based method and composition for treating pathogens)

IT Drugs
(conjugates with pigments; phototherapy-based method and composition for treating pathogens)

IT Immunoglobulins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conjugates, with pigments; phototherapy-based method and composition for treating pathogens)

IT Flours and Meals
(corn, dextrose; phototherapy-based method and composition for treating pathogens)

IT Potato (Solanum tuberosum)
(dextrose; phototherapy-based method and composition for treating pathogens)

IT Nail (anatomical)
(disease, onychomycosis; phototherapy-based method and composition for treating pathogens)

IT Hair preparations
(dyes; phototherapy-based method and composition for treating pathogens)

IT Porphyrins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hematoporphyrins; phototherapy-based method and composition for treating pathogens)

IT Skin, disease
(infection; phototherapy-based method and composition for treating pathogens)

IT Corn
(meal, dextrose; phototherapy-based method and composition for treating pathogens)

IT Nail (anatomical)
(onychomycosis; phototherapy-based method and composition for treating pathogens)

IT Drug delivery systems
(oral; phototherapy-based method and composition for treating pathogens)

IT Antimalarials
Drug delivery systems
Dyes
IR laser radiation
Nail (anatomical)
Nutrients
Pathogen
Photodynamic therapy
Phototherapy
Pigments, nonbiological
Stains, biological
Trichophyton mentagrophytes
Trichophyton rubrum
UV radiation
(phototherapy-based method and composition for treating pathogens)

IT Carotenes, biological studies
Chlorophylls, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(phototherapy-based method and composition for treating pathogens)

IT Foot
Foot
Nail (anatomical)
Nail (anatomical)
(toenail; phototherapy-based method and composition for treating pathogens)

IT Drug delivery systems
(topical; phototherapy-based method and composition for treating pathogens)

IT 9002-89-5, Polyvinyl alcohol
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(loctophenol cotton blue with; phototherapy-based method and composition for treating pathogens)

IT 50-99-7, Dextrose, biological studies 57-13-6, Urea, biological studies
61-73-4, Methylene blue 69-72-7, Salicylic acid, biological

studies 76-59-5, Bromthymol blue 83-88-5, Riboflavin, biological studies 85-83-6, Scarlet red 88-89-1, Picric acid 92-84-2D, Phenothiazine, derivs. 106-60-5, 5-Aminolevulinic acid 115-40-2, Bromcresol purple 143-74-8, Phenol red 314-13-6, Evans blue 479-61-8D, derivs. 502-65-8, Lycopene 569-61-9, Pararosaniline chloride 574-93-6, Phthalocyanine 633-03-4, Brilliant green 2030-63-9, Clofazimine 2412-14-8, Thiopyronin 4197-24-4 7439-89-6, Iron, biological studies 7439-89-6D, Iron, salts, biological studies 7439-97-6, Mercury, biological studies 7440-22-4, Silver, biological studies 7440-50-8, Copper, biological studies 7440-57-5, Gold, biological studies 7440-66-6, Zinc, biological studies 7440-69-9, Bismuth, biological studies 7664-93-9, Sulfuric acid, biological studies 9005-65-6, Tween 80 10118-90-8, Minocycline 14320-04-8D, Zinc phthalocyanine, derivs. 19660-77-6, Chlorin e6 25550-58-7, Dinitrophenol 37251-80-2, Toluidine blue 39378-61-5, Bromcresol 51811-82-6, Giemsa's stain 110230-98-3 122341-38-2
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(phototherapy-based method and composition for treating pathogens)

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE


- (1) Boyer; US 5189029 A 1993 HCPLUS
- (2) Hayes, J; US 5464610 A 1995 HCPLUS
- (3) Lewis; US 5235045 A 1993 HCPLUS
- (4) Moberg; US 5525635 A 1996 HCPLUS
- (5) Wohlrab; US 5346692 A 1994 HCPLUS

IT 69-72-7, Salicylic acid, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(phototherapy-based method and composition for treating pathogens)

RN 69-72-7 HCPLUS

CN Benzoic acid, 2-hydroxy- (9CI) (CA INDEX NAME)



L39 ANSWER 5 OF 5 HCPLUS COPYRIGHT 2005 ACS on STN

AN 1993:66891 HCPLUS

DN 118:66891

ED Entered STN: 16 Feb 1993

TI Pharmaceutical ointments for treatment of onychomycosis

IN Guo, Yi; Fan, Zhiqin; Guo, Dongmei; et al.

PA Peop. Rep. China

SO Faming Zhanli Shengqing Gongkai Shuomingshu, 6 pp.

CODEN: CNXXEV

DT Patent

LA Chinese

IC ICM A61K035-78

CC 63-6 (Pharmaceuticals)

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----
PI CN 1063820	A	19920826	CN 1991-100678	19910130
PRAI CN 1991-100678			19910130	

CLASS


PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
-----	-----	-----

CN 1063820	ICM	A61K035-78
------------	-----	------------

AB A pharmaceutical ointment for treating onychomycosis is manufactured consisting of lead oxide mixture 3-5, FeSO4.7H2O 2-5, alunite 3-5, sublime S 2-4, KAl(SO4)2 2-4, heated gypsum 2-4, orpiment 2-4, CuCO3.Cu(OH)2 2-4, cinnabar 1-3, Phellodendron amurense bark 5-5, Stemonae japonica 3-5, Impatiens balsamina flower 3-5, Typhonium giganteum tuber 2-4,

Dictamnus dasycarpus root bark 2-4, Angelica dahurica root 2-4, Biota orientalis leaves or young stems 2-4, Burseraceae resin 0.5-7, Commiphore myrrha resin 0.5-4, urea 30-50, lactic acid 1-2, benzoic acid 0.1-0.2, o-hydroxybenzoic acid 5-10, lanolin 15-40, white petrolatum 3-10, beeswax 5-15, and mineral waxes 5-15%. The preps. were clin. tested.

ST onychomycosis ointment salt natural product
 IT Angelica dahurica
 Dictamnus dasycarpus
 Impatiens balsamina
 Platycladus orientalis
 Stemona japonica
 Typhonium giganteum
 (pharmaceutical ointments containing, for onychomycosis)
 IT Burseraceae
 Commiphora myrrha
 (resins, pharmaceutical ointments containing, for onychomycosis)
 IT Nail (anatomical)
 (disease, onychomycosis, treatment of,
 pharmaceutical ointments containing salts and plant parts for)
 IT Pharmaceutical dosage forms
 (ointments, lead oxide and other substances in, for
 onychomycosis treatment)
 IT Cork tree (Phellodendron)
 (P. amurensis, pharmaceutical ointments containing, for
 onychomycosis)
 IT 50-21-5, Lactic acid, biological studies 57-13-6, Urea, biological
 studies 65-85-0, Benzoic acid, biological studies 69-72-7,
 o-Hydroxybenzoic acid, biological studies 1302-91-6, Alunite
 1335-25-7, Lead oxide 7704-34-9, Sulfur, biological studies
 10124-49-9, Iron sulfate 12069-69-1 12255-89-9, Orpiment 13397-24-5,
 Gypsum, biological studies 15007-61-1, Potassium aluminum sulfate
 19122-79-3, Cinnabar
 RL: BIOL (Biological study)
 (pharmaceutical ointments containing, for onychomycosis)
 IT 69-72-7, o-Hydroxybenzoic acid, biological studies
 RL: BIOL (Biological study)
 (pharmaceutical ointments containing, for onychomycosis)
 RN 69-72-7 HCPLUS
 CN Benzoic acid, 2-hydroxy- (9CI) (CA INDEX NAME)



=> b uspatall
 FILE 'USPATFULL' ENTERED AT 11:17:54 ON 21 JUL 2005
 CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 11:17:54 ON 21 JUL 2005
 CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

=> d bib abs fhitstr 144 tot

L44 ANSWER 1 OF 2 USPATFULL on STN
 AN 2004:126540 USPATFULL
 TI Composition and method for the treatment of onychomycosis in
 animals
 IN Tarbet, Bryon J., Highland, UT, UNITED STATES
 PI US 2004096519 A1 20040520
 AI US 2003-706708 A1 20031111 (10)
 RLI Division of Ser. No. US 2000-545486, filed on 10 Apr 2000, GRANTED, Pat.


No. US 6680073
 PRAI US 1999-128604P 19990408 (60)
 DT Utility
 FS APPLICATION
 LREP Kenneth Tarbet, 1652 Seattle Slew Way, Oceanside, CA, 92057
 CLMN Number of Claims: 26
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 355

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to a composition and method for the treatment of white line disease, including ailments such as **onychomycosis**, sporotichosis, hoof rot, jungle rot, pseudallescheria boydii, scopulariopsis or athletes foot. The composition of the present invention is useful for the treatment of fungal infections such as **onychomycosis** in warm blooded animals such as humans and horses. The method of the present invention is directed to the application of a therapeutic amount of the present composition.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 69-72-7, Salicylic acid, biological studies
 (solns. for treatment of **onychomycosis** in animals)
 RN 69-72-7 USPATFULL
 CN Benzoic acid, 2-hydroxy- (9CI) (CA INDEX NAME)




L44 ANSWER 2 OF 2 USPATFULL on STN
 AN 2004:14947 USPATFULL
 TI Composition and method for the treatment of **onychomycosis** in animals
 IN Tarbet, Bryon J., 11066 N. 5730 W., Highland, UT, United States 84003
 PI US 6680073 B1 20040120
 AI US 2000-545486 20000410 (9)
 PRAI US 1999-128604P 19990408 (60)
 DT Utility
 FS GRANTED
 EXNAM Primary Examiner: Levy, Neil S.
 LREP Tarbet, Ken H.
 CLMN Number of Claims: 12
 ECL Exemplary Claim: 1
 DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
 LN.CNT 266

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to a composition and method for the treatment of white line disease, including ailments such as **Onychomycosis**, sporotichosis, hoof rot, jungle rot, pseudallescheria boydii, scopulariopsis or athletes foot. The composition of the present invention is useful for the treatment of fungal infections such as **Onychomycosis** in warm blooded animals such as humans and horses. The method of the present invention is directed to the application of a therapeutic amount of the present composition.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 69-72-7, Salicylic acid, biological studies
 (solns. for treatment of **onychomycosis** in animals)
 RN 69-72-7 USPATFULL
 CN Benzoic acid, 2-hydroxy- (9CI) (CA INDEX NAME)



=> d bib abs hitstr l47 tot

L47 ANSWER 1 OF 3 USPATFULL on STN
 AN 2004:177913 USPATFULL
 TI Seborrheic keratosis treatment
 IN Ancira, Margaret, Phoenix, AZ, UNITED STATES
 Miller, Mickey, Paradise Valley, AZ, UNITED STATES
 PI US 2004137077 A1 20040715
 AI US 2003-684136 A1 20031009 (10)
 RLI Continuation-in-part of Ser. No. US 2002-72829, filed on 8 Feb 2002,
 PENDING

PRAI US 2001-267978P 20010209 (60)

DT Utility

FS APPLICATION

LREP STINSON MORRISON HECKER LLP, ATTN: PATENT GROUP, 1201 WALNUT STREET,
 SUITE 2800, KANSAS CITY, MO, 64106-2150

CLMN Number of Claims: 79

ECL Exemplary Claim: 1

DRWN 1 Drawing Page(s)

LN.CNT 1505

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The subject of the present invention is seborrheic keratosis removal and prevention utilizing safe dependable effective biocompatible treatments with no scarring, bleeding, burning, freezing, shocking, and hypopigmentation or hyperpigmentation.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 69-72-7D, Salicylic acid, alkyl derivs.

(as melanin inhibitor, composition further containing; seborrheic keratosis treatment using hydrogen peroxide)

RN 69-72-7 USPATFULL


CN Benzoic acid, 2-hydroxy- (9CI) (CA INDEX NAME)



IT 69-72-7, Salicylic acid, biological studies
 (composition further containing; seborrheic keratosis treatment using hydrogen peroxide)

RN 69-72-7 USPATFULL

CN Benzoic acid, 2-hydroxy- (9CI) (CA INDEX NAME)




L47 ANSWER 2 OF 3 USPATFULL on STN

AN 2000:91943 USPATFULL

TI Phototherapy based method for treating pathogens and composition for

effecting same
 IN Lurie, Raz, Tel Aviv, Israel
 PA Dermatolazer Technologies Ltd., Tel Aviv, Israel (non-U.S. corporation)
 PI US 6090788 20000718
 AI US 1999-343199 19990630 (9)
 RLI Continuation of Ser. No. WO 1998-US14162, filed on 13 Jul 1998
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Peselev, Elli
 LREP Friedman, Mark M.
 CLMN Number of Claims: 23
 ECL Exemplary Claim: 1
 DRWN 2 Drawing Figure(s); 2 Drawing Page(s)
 LN.CNT 1076
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB A method for treating an area of skin or nail affected with a pathogen, the method comprising the step of irradiating the area of skin or nail with a light beam having at least one wavelength absorbable by the pathogen.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 IT 69-72-7, Salicylic acid, biological studies
 (phototherapy-based method and composition for treating pathogens)
 RN 69-72-7 USPATFULL
 CN Benzoic acid, 2-hydroxy- (9CI) (CA INDEX NAME)



L47 ANSWER 3 OF 3 USPAT2 on STN
 AN 2003:120772 USPAT2
 TI Compositions and methods for enhancing drug delivery across and into epithelial tissues
 IN Rothbard, Jonathan B., Cupertino, CA, United States
 Wender, Paul A., Menlo Park, CA, United States
 McGrane, P. Leo, Mountain View, CA, United States
 Sista, Lalitha V. S., Sunnyvale, CA, United States
 Kirschberg, Thorsten A., Mountain View, CA, United States
 PA Cellgate, Inc., Sunnyvale, CA, United States (U.S. corporation)
 PI US 6759387 B2 20040706
 AI US 2002-209421 20020730 (10)
 RLI Continuation of Ser. No. US 2000-648400, filed on 24 Aug 2000, now patented, Pat. No. US 6593292
 PRAI US 1999-150510P 19990824 (60)
 DT Utility
 FS GRANTED
 EXNAM Primary Examiner: Russel, Jeffrey E.
 LREP Townsend and Townsend and Crew LLP
 CLMN Number of Claims: 31
 ECL Exemplary Claim: 1
 DRWN 41 Drawing Figure(s); 23 Drawing Page(s)
 LN.CNT 3255
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides compositions and methods for enhancing delivery of drugs and other agents across epithelial tissues, including the skin, gastrointestinal tract, pulmonary epithelium, and the like. The compositions and methods are also useful for delivery across endothelial tissues, including the blood brain barrier. The compositions and methods employ a delivery enhancing transporter that has sufficient guanidino or amidino sidechain moieties to enhance delivery of a compound conjugated to the reagent across one or more layers of the tissue, compared to the


non-conjugated compound. The delivery-enhancing polymers include, for example, poly-arginine molecules that are preferably between about 6 and 25 residues in length (SEQ ID NO:50).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 69-72-7, Salicylic acid, biological studies
(compns. and methods for enhancing drug delivery across and into epithelial tissues)

RN 69-72-7 USPAT2

CN Benzoic acid, 2-hydroxy- (9CI) (CA INDEX NAME)



=> b home
FILE 'HOME' ENTERED AT 11:18:41 ON 21 JUL 2005

=>